0001818331-25-000108 | 10-Q | XBRL Viewer

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2025

As of June 30, 2025, long-term debt matures as follows:


2025 (remainder of year)	$	608
2026	1,235
2027	1,260
2028	51,285
2029	762

Total debt	55,150
Less: current portion of long-term debt	(1,223)
Less: long-term debt issuance costs	(2,244)
Total long-term debt, net of current portion	$	51,683

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The CODM evaluates segment performance based on revenue and adjusted gross profit.


	Three months ended June 30,
	2025						2024
	GeneDx		Other		Total		GeneDx		Other		Total
Revenue	$	101,784	$	908	$	102,692	$	68,924	$	1,590	$	70,514
Adjusted cost of services	29,964		244		30,208		26,523		145		26,668
Adjusted gross profit (1)	71,820		664		72,484		42,401		1,445		43,846

Reconciliations:
Depreciation and amortization					1,389						808
Stock-based compensation					193						86

Gross profit					$	70,902					$	42,952


	Six months ended June 30,
	2025						2024
	GeneDx		Other		Total		GeneDx		Other		Total
Revenue	$	188,899	$	908	$	189,807	$	130,385	$	2,551	$	132,936
Adjusted cost of services	57,360		244		57,604		50,622		145		50,767
Adjusted gross profit (1)	131,539		664		132,203		79,763		2,406		82,169

Reconciliations:
Depreciation and amortization					2,464						1,624
Stock-based compensation					361						134
Restructuring costs					—						48
Gross profit					$	129,378					$	80,363

(1)Adjusted cost of services and adjusted gross profit exclude depreciation and amortization expense, stock-based compensation expense and restructuring costs.

Business Combinations (Tables)

6 Months Ended

Jun. 30, 2025

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table presents the allocation of the purchase price to the estimated fair value of the assets acquired and liabilities assumed as of the Merger Date:


Cash and cash equivalents	$	272
Accounts receivable	510
Prepaid expenses and other current assets	334
Property and equipment, net	12
Other assets	59
Intangible assets, net	25,500
Operating lease right-of-use assets	854
Accounts payable and accrued expenses	(1,147)
Deferred revenue	(1,609)

Operating lease liability	(854)
Fair value of net assets acquired	23,931
Goodwill (1)	12,926
Aggregate purchase price	$	36,857

(1)The goodwill recorded relating to the Merger is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the Merger Date, and represents future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. The goodwill recorded is not deductible for tax purposes.

Schedule of Fair Values and Useful Lives of the Acquired Intangible Assets

The following table reflects the fair values and useful lives of the acquired intangible assets identified based on the Company’s preliminary purchase accounting assessments:


	May 5, 2025		June 30, 2025		Life (in Years)
Trade names and trademarks	$	4,500	$	4,450	15
Developed technology	14,900		14,624		9
Customer relationships	6,100		6,027		14
	$	25,500	$	25,101

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of June 30, 2025:


2025 (remainder of year)	$	1,196
2026	2,391
2027	2,391
2028	2,391
2029	2,391
Thereafter	14,341
Total estimated future amortization expense	$	25,101

Schedule of Pro Forma Financial Information

The following table provides unaudited pro forma financial information for the three and six months ended June 30, 2025 and 2024 as if the Merger had occurred as of January 1, 2024:


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Pro forma revenues	$	103,183	$	72,079	$	191,577	$	135,849
Pro forma net income (loss)	11,112		(31,402)		2,621		(53,972)

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Revenue Disaggregated by Type of Customer

The following table summarizes the Company’s disaggregated revenue by payor category:


	Three months ended June 30,
	2025						2024
	GeneDx		Other1		Total		GeneDx		Other1		Total
Diagnostic test revenue:
Patients with third-party insurance	$	81,104	$	—	$	81,104	$	50,462	$	1,590	$	52,052
Institutional customers	18,380		—		18,380		16,695		—		16,695
Self-pay patients	339		—		339		692		—		692
Total diagnostic test revenue	99,823		—		99,823		67,849		1,590		69,439
Other revenue	1,961		908		2,869		1,075		—		1,075
Total	$	101,784	$	908	$	102,692	$	68,924	$	1,590	$	70,514


	Six months ended June 30,
	2025						2024
	GeneDx		Other1		Total		GeneDx		Other1		Total
Diagnostic test revenue:
Patients with third-party insurance	$	149,163	$	—	$	149,163	$	93,340	$	2,551	$	95,891
Institutional customers	35,984		—		35,984		33,369		—		33,369
Self-pay patients	435		—		435		1,283		—		1,283
Total diagnostic test revenue	185,582		—		185,582		127,992		2,551		130,543
Other revenue	3,317		908		4,225		2,393		—		2,393
Total	$	188,899	$	908	$	189,807	$	130,385	$	2,551	$	132,936

(1)For the three and six months ended June 30, 2024, Other represents revenues associated with the Legacy Sema4 operating segment. For the three and six months ended June 30, 2025, revenues of the Fabric Genomics and Legacy Sema4 operating segments. See Note 15, “Segment Reporting” for more information.

Earnings (Loss) per Share (Tables)

6 Months Ended

Jun. 30, 2025

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Earnings (Loss) per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share attributable to common stockholders:


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Numerator:
Net income (loss) attributable to common stockholders	$	10,809	$	(29,173)	$	4,280	$	(49,412)
Denominator:
Basic weighted-average common shares outstanding	28,579,704		26,617,955		28,365,018		26,340,063
Basic earnings (loss) per share	$	0.38	$	(1.10)	$	0.15	$	(1.88)

Diluted weighted-average common shares outstanding	29,753,933		26,617,955		29,642,555		26,340,063
Diluted earnings (loss) per share	$	0.36	$	(1.10)	$	0.14	$	(1.88)

Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Earnings (Loss) per Share

The following table summarizes the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted earnings (loss) per share attributable to common stockholders for the period presented as the effect would be anti-dilutive:


	Three and six months ended June 30,
	2025	2024
Outstanding options and restricted stock units	17,072	2,557,738
Outstanding warrants	666,515	666,515
Outstanding 2021 ESPP shares	—	29,267
Total	683,587	3,253,520

Organization and Description of Business	6 Months Ended
Organization and Description of Business	Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business GeneDx Holdings Corp., through its subsidiary GeneDx, LLC, is a leading genomics company—one that sits at the intersection of diagnostics and data science, pairing decades of genomic expertise with an ability to interpret clinical data at scale. The Company believes that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, the Company’s industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The Company operates with conviction that what is best for patients must be embedded in every aspect of our work. In support of these beliefs, we value equitability, simplicity and transparency. Unless otherwise stated herein or unless the context otherwise requires, references in these notes to: •“GeneDx Holdings” refer to GeneDx Holdings Corp., a Delaware corporation; •“Legacy GeneDx” refer to GeneDx, LLC, a Delaware limited liability company, which we acquired on April 29, 2022 (the “Acquisition”); •“Legacy Sema4” refer to Sema4 OpCo Inc., a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and •“we,” “us” and “our,” the “Company” and “GeneDx” refer to GeneDx Holdings and its consolidated subsidiaries. On May 5, 2025 (the “Merger Date”), the Company consummated the transactions contemplated by the Agreement and Plan of Merger, which was entered into on April 15, 2025 (the “Merger Agreement”) by and among the Company, Project Flare Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of the Company, Fabric Genomics, Inc., a Delaware corporation (“Fabric Genomics”), and Martin Reese, as the Agent, pursuant to which, and on the terms and subject to the conditions thereof, the Company acquired Fabric Genomics through the merger of Merger Sub with and into Fabric Genomics, with Fabric Genomics surviving as a wholly-owned subsidiary of the Company (the “Merger”). See Note 3, “Business Combinations” included within this Quarterly Report for further information regarding the Merger.

Stock-Based Compensation

6 Months Ended

Jun. 30, 2025

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-based compensation expense is included within the condensed consolidated statements of operations and comprehensive income (loss) as follows:


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Cost of services	$	193	$	86	$	361	$	134
Research and development	1,422		347		1,841		160
Selling and marketing	1,268		368		1,814		348
General and administrative	4,930		2,307		7,780		2,015
Total stock-based compensation expense1,2	$	7,813	$	3,108	$	11,796	$	2,657

(1)The Company recorded an aggregate reversal of stock-based compensation of $0.2 million and $0.1 million during the three months ended June 30, 2025 and 2024, respectively, and $0.8 million and $3.3 million during the six months ended June 30, 2025 and 2024, respectively, due to forfeiture activities upon employee terminations.

(2)Includes $0.4 million and $0.1 million of expenses related to the 2021 Employee Stock Purchase Plan for the three months ended June 30, 2025 and 2024, respectively, and $0.7 million and $0.1 million of expenses for the six months ended June 30, 2025 and 2024, respectively.

Stock Incentive Plans

The Company maintains the Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”), which allows for grants of stock-based awards. No awards granted under the 2021 Plan are exercisable after 10 years from the date of grant, and the awards granted under the 2021 Plan generally vest over a four-year period on a graded vesting basis; however, the Company also granted certain restricted stock units with vesting terms beginning 12 months from the grant date and vesting immediately on the grant date. On January 1 of each year through 2031, the aggregate number of shares of Class A common stock reserved for issuance under the 2021 Plan may be increased automatically by the number of shares equal to 5% of the total number of shares of all classes of common stock issued and outstanding immediately preceding December 31. In January 2025, the number of Class A common stock reserved for future issuance under the 2021 Plan automatically increased by 1,400,827 shares.

The Company also maintains the 2023 Equity Inducement Plan (the “Equity Inducement Plan”), which allows for grants of equity awards of the Company’s Class A common stock to individuals who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.

As of June 30, 2025, there was an aggregate of 3,007,791 shares available for grants of stock options or other awards under the 2021 Plan and Equity Inducement Plan.

Stock Options

All stock options granted under the 2021 Plan are accounted for as time-based equity awards. The following table summarizes the stock option activity during the six months ended June 30, 2025:


	Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value
Outstanding at December 31, 2024	341,280	$	44.83	5.99	$	12,429
Granted	—	$	—
Exercised	(35,432)	$	22.63
Forfeited and canceled	—	$	—
Outstanding at June 30, 2025	305,848	$	47.33	5.50	$	15,108
Options exercisable at June 30, 2025	275,244	$	44.68	5.33	$	14,058

Non-vested options outstanding as of June 30, 2025 were 30,604 with a weighted-average grant-date fair value of $45.87. As of June 30, 2025, unrecognized stock-based compensation cost related to the unvested portion of the Company’s stock options was $0.2 million, which is expected to be recognized on a graded-vesting basis over a weighted-average period of 0.7 years.

The weighted-average grant-date fair value and total fair value of options with tranches vested during the six months ended June 30, 2025 was $46.76 and $0.4 million, respectively.

There were no options granted during the six months ended June 30, 2025. The aggregate intrinsic value of options exercised during the six months ended June 30, 2025 was $2.4 million, and is calculated based on the difference between the exercise price and the fair value of the Company’s Class A common stock as of the exercise date. There were no options forfeited or canceled during the six months ended June 30, 2025.

Restricted Stock Units

Restricted stock units granted under the 2021 Plan are accounted for as either time-based restricted stock units (“RSUs”) or performance-based restricted stock units (“PRSUs”). Restricted stock units convert to Class A common stock on a one-for-one basis as the awards vest. The Company measures the fair value of restricted stock units at fair value based on the closing price of the underlying common stock on the grant date. The following table summarizes restricted stock unit activity during the six months ended June 30, 2025:


	Restricted Stock Units	Weighted-Average Grant Date-Fair Value Per Unit
Outstanding at December 31, 2024	1,869,561	$	12.03
Granted1	481,895	$	92.90
Vested	(483,407)	$	14.69
Forfeited	(232,189)	$	15.69
Outstanding at June 30, 2025	1,635,860	$	34.73

(1)Includes 73,677 PRSUs granted during the six months ended June 30, 2025 with a weighted-average grant-date fair value of $98.47.

During the six months ended June 30, 2025, the Company approved an award of 73,677 PRSUs to certain executives. The grant date fair value of the PRSUs is based on the fair value of the Company’s Class A common stock on the grant date. The awards have both time-based and performance-based vesting conditions. The actual number of shares earned on vesting ranges from 0% to 200% of the target number of shares granted, depending on the attainment of specified performance goals established for the years ending December 31, 2025 and 2026.

The total fair value of restricted stock units vested during the six months ended June 30, 2025 was $7.1 million. As of June 30, 2025, unrecognized stock-based compensation expense related to the Company’s restricted stock units was $41.1 million, which is expected to be recognized on a graded-vesting basis over a weighted-average period of 2.0 years.

Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) authorizes the issuance of shares of Class A common stock pursuant to purchase rights granted to employees. On January 1 of each year through 2031, the aggregate number of shares of Class A common stock reserved for issuance under the 2021 ESPP may be increased automatically by the number of shares equal to 1% of the total number of shares of all classes of common stock issued and outstanding immediately preceding December 31. In January 2025, the number of class A common stock reserved for future issuance under the 2021 ESPP automatically increased by 280,165 shares.

The 2021 ESPP became open for enrollment in April 2024. Under the 2021 ESPP, eligible employees may purchase shares of the Company’s Class A common stock at a discount through payroll deductions during each discrete six-month offering period. The purchase price under each discrete offering period is equal to 85% of the lesser of the fair market value of the Class A common stock on the first and last day of the offering period.

The Company issued 22,674 shares of Class A common stock under the 2021 ESPP during the three and six months ended June 30, 2025. As of June 30, 2025, a total of 827,322 shares of Class A common stock have been reserved for future issuance under the 2021 ESPP.

Supplemental Financial Information - Schedule of Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Warrant liability	$ 1,539	$ 3,519
Long-term contingent consideration liability	1,736	0
Third party payor reserve, long-term	0	2,000
Total	$ 3,275	$ 5,519

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

The following table reflects, as of June 30, 2025, the carrying values and remaining useful lives of acquired intangible assets:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Value		Weighted-Average Amortization Period (in years)
Tradenames and trademarks	$	54,500	$	(9,946)	$	44,554	13.0
Developed technology	62,900		(19,276)		43,624		6.2
Customer relationships	104,100		(15,589)		88,511		16.6
Total intangible assets	$	221,500	$	(44,811)	$	176,689	13.1

Amortization expense for tradenames and trademarks and developed technology of $2.6 million and $2.3 million was recorded in general and administrative for the three months ended June 30, 2025 and 2024, respectively, and $4.9 million and $4.6 million for the six months ended June 30, 2025 and 2024, respectively, within the condensed consolidated statements of operations and comprehensive income (loss). Amortization expense for customer relationships of $1.3 million and $1.2 million was recorded in selling and marketing for the three months ended June 30, 2025 and 2024, respectively, and $2.5 million for both the six months ended June 30, 2025 and 2024, within the condensed consolidated statements of operations and comprehensive income (loss).

The acquisition of Fabric Genomics resulted in the recognition of $12.9 million of goodwill as of the Merger Date. There were no changes to the carrying amount of goodwill between the Merger Date and June 30, 2025. See Note 3, “Business Combinations” included within this Quarterly Report for further information.

Long-Term Debt

6 Months Ended

Jun. 30, 2025

Debt Disclosure [Abstract]

Long-Term Debt

As of June 30, 2025, long-term debt matures as follows:


2025 (remainder of year)	$	608
2026	1,235
2027	1,260
2028	51,285
2029	762

Total debt	55,150
Less: current portion of long-term debt	(1,223)
Less: long-term debt issuance costs	(2,244)
Total long-term debt, net of current portion	$	51,683

Perceptive Term Loan Facility

On October 27, 2023 (the “Closing Date”), the Company entered into the Perceptive Term Loan Facility. An initial tranche of $50.0 million (the “Tranche A Loan”) was funded under the Perceptive Term Loan Facility on the Closing Date. In addition to the Tranche A Loan, the Perceptive Term Loan Facility included an additional tranche of $25.0 million (the “Tranche B Loan,” and together with the Tranche A Loan, the “Term Loans”), which was accessible by the Company through December 31, 2024 so long as the Company satisfied certain customary conditions precedent, including a specified revenue milestone (the funding date of the Tranche B Loan, the “Tranche B Borrowing Date”). Although the requirements for the Tranche B funding were met, the Company did not seek the additional funding.

The Perceptive Term Loan Facility has a maturity date of October 27, 2028 (the “Maturity Date”) and provides for an interest-only period during the term of the loan with principal due at the maturity date. The Company’s net proceeds from the Tranche A Loan were approximately $48.8 million, after deducting debt issuance costs and expenses.

Interest Rate

The Perceptive Term Loan Facility accrues interest at an annual rate equal to the sum of (a) Term SOFR (as defined in the Credit Agreement) and (b) an applicable margin of 7.5% (the “Applicable Margin”). Accrued interest on the Term Loans is payable monthly in arrears. Upon an Event of Default (as defined in the Credit Agreement), the Applicable Margin will automatically increase by an additional 4% per annum.

Amortization and Prepayment

Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. On the Maturity Date, the Company is required to pay Perceptive the aggregate outstanding principal amount of the Tranche A Loan and all accrued and unpaid interest thereon. The Tranche A Loan may be prepaid at any time, subject to a prepayment premium equal to 0% to 10% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.

Security Instruments and Warrant

In connection with the Credit Agreement, the Company also entered into a Security Agreement, dated as of the Closing Date, with Perceptive, pursuant to which all of its obligations under the Credit Agreement are secured by a first lien perfected security interest on substantially all of its existing and after-acquired assets, subject to customary exceptions.

On the Closing Date, as consideration for the Credit Agreement, the Company issued the Perceptive Warrants to Perceptive, which allowed Perceptive to purchase up to 1,200,000 Warrant Shares. The 800,000 Initial Warrant Shares vested and became exercisable on the Closing Date and the 400,000 Additional Warrant Shares would have potentially vested and become exercisable on the Tranche B Borrowing Date. As the Company did not seek the additional funding from the Tranche B Loan, the Additional Warrant Shares did not vest and are not exercisable.

On April 30, 2024, Perceptive provided the Company with a notice to exercise the Initial Warrant Shares at an aggregate exercise price of $2.5 million and instructed the Company to withhold a number of Initial Warrant Shares as payment for the aggregate exercise price. As a result, the Company issued 645,414 shares of its Class A common stock in satisfaction of the cashless exercise in respect of the Initial Warrant Shares. See Note 5, “Fair Value Measurements” included within this Quarterly Report for further information.

Connecticut Department of Economic and Community Development Funding Commitment

In June 2017, ISMMS assigned a loan funding commitment from the DECD to the Company (the “DECD Loan Agreement”) to support the Genetic Sequencing Laboratory Project in Branford, Connecticut, with funding based on the achievement of certain project development phases. This commitment was collateralized by a security interest in certain machinery and equipment the Company acquired from ISMMS, as defined in a separate security agreement.

In January 2023, the Company amended the DECD Loan Agreement (as amended, the “2022 Amended DECD Loan Agreement”). The terms of the 2022 Amended DECD Loan Agreement require the Company to make interest-only payments through July 2024 and require the Company to make principal and interest payments commencing in August 2024 through July 2029 at a fixed annual interest rate of 2.0%.

During the three and six months ended June 30, 2025, the Company made principal payments totaling $0.3 million and $0.6 million, respectively. The outstanding loan balance from the 2022 Amended DECD Loan Agreement was $5.2 million as of June 30, 2025.

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Acquired Intangible Assets

The following table reflects, as of June 30, 2025, the carrying values and remaining useful lives of acquired intangible assets:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Value		Weighted-Average Amortization Period (in years)
Tradenames and trademarks	$	54,500	$	(9,946)	$	44,554	13.0
Developed technology	62,900		(19,276)		43,624		6.2
Customer relationships	104,100		(15,589)		88,511		16.6
Total intangible assets	$	221,500	$	(44,811)	$	176,689	13.1

Long-Term Debt - Loan and Security Agreement (Details) - USD ($) $ in Millions	Apr. 30, 2024	Oct. 27, 2023	Jun. 30, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Common stock, issued (in shares)			28,708,058	28,016,545
Initial Warrant Shares
Debt Instrument [Line Items]
Aggregate exercise price	$ 2.5
Common stock, issued (in shares)	645,414
Credit Agreement \| Perceptive Term Loan Facility
Debt Instrument [Line Items]
Revolving credit facility		$ 75.0
Debt instrument, basis spread on variable rate		7.50%
Debt instrument, interest rate, increase (decrease)		4.00%
Credit Agreement \| Perceptive Term Loan Facility \| Perceptive Warrant Liability
Debt Instrument [Line Items]
Number of shares to purchase (in shares)		1,200,000
Credit Agreement \| Perceptive Term Loan Facility \| Initial Warrant Shares
Debt Instrument [Line Items]
Number of shares to purchase (in shares)		800,000
Credit Agreement \| Perceptive Term Loan Facility \| Additional Warrant Shares
Debt Instrument [Line Items]
Number of shares to purchase (in shares)		400,000
Credit Agreement \| Perceptive Term Loan Facility \| Minimum
Debt Instrument [Line Items]
Prepayment premium (as percent)		0.00%
Credit Agreement \| Perceptive Term Loan Facility \| Maximum
Debt Instrument [Line Items]
Prepayment premium (as percent)		10.00%
Credit Agreement, Tranche A Loan \| Perceptive Term Loan Facility
Debt Instrument [Line Items]
Revolving credit facility		$ 50.0
Proceeds from loan		48.8
Credit Agreement, Tranche B Loan \| Perceptive Term Loan Facility
Debt Instrument [Line Items]
Revolving credit facility		$ 25.0

Property and Equipment, net - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 2,286	$ 1,712	$ 4,458	$ 3,454
Cost of services
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	1,389	808	2,464	1,624
Research and development
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	209	211	581	407
General and administrative
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 688	$ 693	$ 1,413	$ 1,423

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income	Class A common stock	Class A common stock Common Stock
Beginning balance (in shares) at Dec. 31, 2023						25,978,863
Beginning balance at Dec. 31, 2023	$ 228,017	$ 1,527,778	$ (1,300,188)	$ 425		$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(49,412)		(49,412)
Common stock issued pursuant to stock option exercises (in shares)						31,946
Common stock issued pursuant to stock option exercises	161	161
Common stock issued pursuant to Perceptive warrant exercise (in shares)						645,414
Common stock issued pursuant to Perceptive warrant exercise	12,586	12,586
Stock-based compensation expense	2,657	2,657
Vested restricted stock units converted to common stock (in shares)						270,160
Other comprehensive (loss) income, net of tax	34			34
Ending balance (in shares) at Jun. 30, 2024						26,926,383
Ending balance at Jun. 30, 2024	194,043	1,543,182	(1,349,600)	459		$ 2
Beginning balance (in shares) at Mar. 31, 2024						26,122,348
Beginning balance at Mar. 31, 2024	207,217	1,527,351	(1,320,427)	291		$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(29,173)		(29,173)
Common stock issued pursuant to stock option exercises (in shares)						27,069
Common stock issued pursuant to stock option exercises	137	137
Common stock issued pursuant to Perceptive warrant exercise (in shares)						645,414
Common stock issued pursuant to Perceptive warrant exercise	12,586	12,586
Stock-based compensation expense	3,108	3,108
Vested restricted stock units converted to common stock (in shares)						131,552
Other comprehensive (loss) income, net of tax	168			168
Ending balance (in shares) at Jun. 30, 2024						26,926,383
Ending balance at Jun. 30, 2024	$ 194,043	1,543,182	(1,349,600)	459		$ 2
Beginning balance (in shares) at Dec. 31, 2024	28,016,545					28,016,545
Beginning balance at Dec. 31, 2024	$ 245,247	1,596,889	(1,352,474)	830		$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,280		4,280
Common stock issued pursuant to stock option exercises (in shares)					35,432	35,432
Common stock issued pursuant to stock option exercises	800	800
Stock-based compensation expense	11,796	11,796
Vested restricted stock units converted to common stock (in shares)						483,407
Issuance of common stock pursuant to employee stock purchase plan (in shares)						22,674
Issuance of common stock pursuant to employee stock purchase plan	1,262	1,262
Issuance of common stock in ATM offering, net of issuance costs (in shares)						150,000
Issuance of common stock in ATM offering, net of issuance costs	13,766	13,766
Other comprehensive (loss) income, net of tax	$ (18)			(18)
Ending balance (in shares) at Jun. 30, 2025	28,708,058					28,708,058
Ending balance at Jun. 30, 2025	$ 277,133	1,624,513	(1,348,194)	812		$ 2
Beginning balance (in shares) at Mar. 31, 2025						28,530,337
Beginning balance at Mar. 31, 2025	257,405	1,615,501	(1,359,003)	905		$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	10,809		10,809
Common stock issued pursuant to stock option exercises (in shares)						1,990
Common stock issued pursuant to stock option exercises	65	65
Stock-based compensation expense	7,813	7,813
Vested restricted stock units converted to common stock (in shares)						153,057
Issuance of common stock pursuant to employee stock purchase plan (in shares)						22,674
Issuance of common stock pursuant to employee stock purchase plan	1,262	1,262
Issuance of common stock in ATM offering, net of issuance costs	(128)	(128)
Other comprehensive (loss) income, net of tax	$ (93)			(93)
Ending balance (in shares) at Jun. 30, 2025	28,708,058					28,708,058
Ending balance at Jun. 30, 2025	$ 277,133	$ 1,624,513	$ (1,348,194)	$ 812		$ 2

Property and Equipment, net - Scheduled of Components (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 62,955	$ 53,200
Less: accumulated depreciation and amortization	(22,835)	(20,307)
Property and equipment, net	40,120	32,893
Laboratory equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	24,292	18,267
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	14,685	14,655
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	8,269	6,912
Building under finance lease
Property, Plant and Equipment [Line Items]
Total property and equipment	4,529	4,529
Equipment under finance leases
Property, Plant and Equipment [Line Items]
Total property and equipment	1,557	3,293
Furniture, fixtures and other equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	584	584
Construction in-progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 9,039	$ 4,960

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2025
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party expenses include the purchase of diagnostic testing kits and lab materials from Twist Biosciences (“Twist”). Transactions with Twist are at arm’s length and represent market rates. The Company incurred $1.7 million and $4.2 million in purchases and $2.2 million and $4.1 million was recorded in cost of services for the three and six months ended June 30, 2025, respectively. The Company incurred $2.6 million and $5.1 million in purchases and $1.7 million and $2.8 million was recorded in cost of services for the three and six months ended June 30, 2024, respectively. Payables due as of June 30, 2025 and December 31, 2024 were $1.2 million and $0.7 million, respectively.

Fair Value Measurements - Schedule of 3 Inputs Used in the Valuation of the Contingent Consideration (Details) - Fabric Genomics - Level 3	Jun. 30, 2025 year Years	May 05, 2025 Years
Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.040	0.039
Expected term (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	1.2	1.4
Equity volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.980	1.070
Revenue volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.100	0.100
Gross margin volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.200	0.200
Minimum \| Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.038	0.038
Minimum \| Expected term (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.8	1.0
Maximum \| Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.041	0.040
Maximum \| Expected term (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	1.8	2.0

Purchase Commitments and Contingencies (Details) - Software and Equipment Providers $ in Thousands	Jun. 30, 2025 USD ($)
Operating Leased Assets [Line Items]
2025 (remainder of year)	$ 9,236
2026	9,403
2027	4,719
2028	4,039
2029	3,914
Thereafter	978
Total purchase commitments	$ 32,289

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2025
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the SEC regarding interim financial reporting. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP. These condensed financial statements consolidate the operations and accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Unless otherwise noted, all tabular dollars are in thousands, except per share amounts. Certain reclassifications have been made to the prior year condensed consolidated financial statements in order to conform to the current year’s presentation. In the opinion of management, the condensed consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair statement of the financial position and the results of operations of the Company for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”).
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Use of Estimates	Use of Estimates The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the valuation of stock-based awards, the valuation of warrant liabilities and income taxes. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates, judgments and assumptions.
Stock-Based Compensation	Stock-Based Compensation Restricted stock units granted by the Company include time-based restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). PRSUs represent a right to receive a certain number of shares of the Company’s Class A common stock based on the achievement of specified performance conditions and continued employment during the vesting period. At each reporting period, the Company assesses the probability of the achievement of such performance conditions and records expense for the awards if it is probable that such performance conditions will be achieved.
Business Combinations	Business Combinations The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company’s management, which consider estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rate, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.
Goodwill	Goodwill In accordance with ASC 350, Intangibles – Goodwill and Other, the Company’s goodwill is not amortized but is tested for impairment on an annual basis, or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company performs an annual impairment review of goodwill during the fourth fiscal quarter, or more frequently if business factors indicate.
Concentration of Credit Risk	Concentration of Credit Risk The Company assesses both the self-pay patient and, if applicable, the third-party payor groups that reimburses the Company on the patient’s behalf when evaluating concentration of credit risk. Significant patients and payor groups are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of June 30, 2025 and December 31, 2024 were primarily from large managed care insurance companies, institutional billed accounts, and data arrangements. The Company does not require collateral as a means to mitigate customer credit risk.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-09, Income Taxes – Improvements to Income Tax Disclosures (“ASU 2023-09”). The standard requires additional disclosures around disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 will be effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this pronouncement on a prospective basis, and will include the additional disclosures as required in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. The Company does not expect the amended guidance to have a material impact on its consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Disaggregation of Income Statement Expenses (“ASU 2024-03”). The standard requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. As revised by the issuance of ASU 2025-01, Income Statement – Reporting Comprehensive Income – Disaggregation of Income Statement Expenses: Clarifying the Effective Date (“ASU 2025-01”) in January 2025, the provisions of ASU 2024-03 will be effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.

Business Combinations - Schedule of Fair Values and Useful Lives of the Acquired Intangible Assets (Details) - USD ($) $ in Thousands			6 Months Ended
	Jun. 30, 2025	May 05, 2025	Jun. 30, 2025
Finite-Lived Intangible Assets [Line Items]
Life (in Years)			13 years 1 month 6 days
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Life (in Years)			13 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Life (in Years)			6 years 2 months 12 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Life (in Years)			16 years 7 months 6 days
Fabric Genomics
Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	$ 25,101	$ 25,500
Fabric Genomics \| Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	$ 4,450	$ 4,500
Life (in Years)	15 years	15 years
Fabric Genomics \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	$ 14,624	$ 14,900
Life (in Years)	9 years	9 years
Fabric Genomics \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	$ 6,027	$ 6,100
Life (in Years)	14 years	14 years

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 74,120	$ 85,212
Marketable securities	60,438	55,973
Accounts receivable	48,028	37,629
Inventory, net	11,932	10,650
Prepaid expenses and other current assets	10,319	8,504
Total current assets	204,837	197,968
Operating lease right-of-use assets	24,978	25,613
Property and equipment, net	40,120	32,893
Goodwill	12,926	0
Intangible assets, net	176,689	158,600
Other assets	4,313	4,306
Total assets	463,863	419,380
Current liabilities:
Accounts payable and accrued expenses	49,239	30,983
Short-term lease liabilities	3,083	3,336
Other current liabilities	19,084	20,498
Total current liabilities	71,406	54,817
Long-term debt, net of current portion	51,683	51,913
Long-term lease liabilities	59,619	60,919
Other liabilities	3,275	5,519
Deferred taxes	747	965
Total liabilities	186,730	174,133
Purchase commitments and contingencies (Note 10)
Stockholders’ Equity:
Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	0	0
Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 28,708,058 and 28,016,545 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	2	2
Additional paid-in capital	1,624,513	1,596,889
Accumulated deficit	(1,348,194)	(1,352,474)
Accumulated other comprehensive income	812	830
Total stockholders’ equity	277,133	245,247
Total liabilities and stockholders’ equity	$ 463,863	$ 419,380

Stock-Based Compensation - Narrative (Details) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) $ / shares shares	Jan. 31, 2025 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested options outstanding (in shares)	30,604	30,604
Weighted average grant (in dollars per share) \| $ / shares	$ 45.87	$ 45.87
Unrecognized stock-based compensation cost on the unvested stock options \| $	$ 0.2	$ 0.2
Weighted-average grant-date fair value (in dollars per share) \| $ / shares		$ 46.76
Fair value of vested options \| $		$ 0.4
Aggregate intrinsic value \| $		$ 2.4
Options forfeited and cancelled (in shares)		0
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average vesting period for compensation cost		8 months 12 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average vesting period for compensation cost		2 years
Stock conversion ratio	1	1
Granted (in shares)		481,895
Fair value of RSU vested in period \| $		$ 7.1
Unvested company stock option \| $	$ 41.1	$ 41.1
Restricted Stock Units (RSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		0.00%
Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		200.00%
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		73,677
Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		0
Options forfeited and cancelled (in shares)		0
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted		0
Weighted average remaining contractual life (years), options exercisable		10 years
Vesting period		4 years
Shares available for grant (in shares)	3,007,791	3,007,791
2021 Plan \| Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares equal to percent		5.00%
Increase in common stock, capital shares reserved for future issuance (in shares)			1,400,827
2021 Employee Stock Purchase Plan \| Outstanding 2021 ESPP shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares equal to percent		1.00%
Number of share reserved for issuance (in shares)	827,322	827,322
2021 Employee Stock Purchase Plan \| Outstanding 2021 ESPP shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period		6 months
Fair market value of the shares on the offering date (as percent)		85.00%
2021 Employee Stock Purchase Plan \| Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in common stock, capital shares reserved for future issuance (in shares)			280,165
2021 Employee Stock Purchase Plan \| Class A common stock \| Outstanding 2021 ESPP shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class A common stock issued under the 2021 ESPP (in shares)	22,674	22,674

Stock-Based Compensation - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares
Stock Options
Forfeited and cancelled (in shares)	0
Aggregate Intrinsic Value
Outstanding \| $	$ 15,108
Options exercisable \| $	$ 14,058
Class A common stock
Stock Options
Beginning balance (in shares)	341,280
Granted (in shares)	0
Exercised (in shares)	(35,432)
Forfeited and cancelled (in shares)	0
Ending balance (in shares)	305,848	341,280
Outstanding, options exercisable at end of period (in shares)	275,244
Weighted-Average Exercise Price
Weighted-average exercise price (in dollars per share) \| $ / shares	$ 44.83
Weighted average exercise price, granted (in dollars per share) \| $ / shares	0
Weighted average exercise price, exercised (in dollars per share) \| $ / shares	22.63
Weighted average exercise price, Forfeited/Expired (in dollars per share) \| $ / shares	0
Weighted-average exercise price (in dollars per share) \| $ / shares	47.33	$ 44.83
Weighted average exercise price, options exercisable (in dollars per share) \| $ / shares	$ 44.68
Weighted-Average Remaining Contractual Life (years)
Weighted average remaining contractual life (years)	5 years 6 months	5 years 11 months 26 days
Weighted average remaining contractual life (years), options exercisable	5 years 3 months 29 days
Aggregate Intrinsic Value
Outstanding \| $		$ 12,429

Stock-Based Compensation - Schedule of Restricted Stock Units (Details)	6 Months Ended
	Jun. 30, 2025 $ / shares shares
Restricted Stock Units (RSUs)
Restricted Stock Units
Outstanding, beginning balance (in shares) \| shares	1,869,561
Granted (in shares) \| shares	481,895
Vested (in shares) \| shares	(483,407)
Forfeited (in shares) \| shares	(232,189)
Outstanding, ending balance (in shares) \| shares	1,635,860
Weighted-Average Grant Date-Fair Value Per Unit
Weighted Average Grant Date Fair Value Per Unit, beginning balance (in dollars per share) \| $ / shares	$ 12.03
Granted (in dollars per share) \| $ / shares	92.90
Vested (in dollars per share) \| $ / shares	14.69
Forfeited (in dollars per share) \| $ / shares	15.69
Weighted Average Grant Date Fair Value Per Unit, ending balance (in dollars per share) \| $ / shares	$ 34.73
Performance-Based Restricted Stock Units
Restricted Stock Units
Granted (in shares) \| shares	73,677
Weighted-Average Grant Date-Fair Value Per Unit
Granted (in dollars per share) \| $ / shares	$ 98.47

Supplemental Financial Information - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Related Party Transaction [Line Items]
Accrued compensation	$ 10,093	$ 16,241
Accrued severance	986	746
Short-term contingent consideration liability	2,553	0
Total	19,084	20,498
Related Party
Related Party Transaction [Line Items]
Other	1,153	668
Nonrelated Party
Related Party Transaction [Line Items]
Other	$ 4,299	$ 2,843

Business Combinations - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2025 USD ($)
Business Combination [Line Items]
Net Carrying Value	$ 176,689
Fabric Genomics
Business Combination [Line Items]
2025 (remainder of year)	1,196
2026	2,391
2027	2,391
2028	2,391
2029	2,391
Thereafter	14,341
Net Carrying Value	$ 25,101

Supplemental Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Accounts payable	$ 3,522	$ 7,954
Accrued expenses	28,116	12,443
Third party payor reserves, short-term	17,601	10,586
Total	$ 49,239	$ 30,983

Long-Term Debt - Schedule of Long-Term Debt Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Debt Disclosure [Abstract]
2025 (remainder of year)	$ 608
2026	1,235
2027	1,260
2028	51,285
2029	762
Total debt	55,150
Less: current portion of long-term debt	(1,223)
Less: long-term debt issuance costs	(2,244)
Total long-term debt, net of current portion	$ 51,683	$ 51,913

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2025	Jul. 24, 2025
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2025
Document Transition Report	false
Entity File Number	001-39482
Entity Registrant Name	GeneDx Holdings Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1966622
Entity Address, Address Line One	333 Ludlow Street
Entity Address, Address Line Two	North Tower
Entity Address, Address Line Three	6th Floor
Entity Address, City or Town	Stamford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06902
City Area Code	888
Local Phone Number	729-1206
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,726,248
Entity Central Index Key	0001818331
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Amendment Flag	false
Class A common stock
Entity Listings [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	WGS
Security Exchange Name	NASDAQ
Warrant
Entity Listings [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share
Trading Symbol	WGSWW
Security Exchange Name	NASDAQ

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Operating activities
Net income (loss)	$ 4,280	$ (49,412)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expense	11,869	10,466
Stock-based compensation expense	11,796	2,657
Change in fair value of warrants and contingent liabilities	(1,081)	10,510
Deferred tax expense (benefit)	202	(272)
Provision for excess and obsolete inventory	123	109
Legal reserves	0	13,450
Change in third party payor reserves	5,014	1,066
Other	1,387	1,738
Change in operating assets and liabilities:
Accounts receivable	(9,889)	6,622
Inventory	(1,404)	(1,654)
Accounts payable and accrued expenses	7,199	(10,871)
Other assets and liabilities	(8,894)	(5,327)
Net cash provided by (used in) operating activities	20,602	(20,918)
Investing activities
Acquisition of business, net of cash acquired	(33,195)	0
Purchases of property and equipment	(8,498)	(1,795)
Purchases of marketable securities	(30,770)	(29,381)
Proceeds from sales of marketable securities	0	598
Proceeds from maturities of marketable securities	26,705	8,720
Net cash used in investing activities	(45,758)	(21,858)
Financing activities
Proceeds from offerings, net of issuance costs	13,766	0
Proceeds from issuance of common stock pursuant to employee stock purchase plan	1,262	0
Exercise of stock options	800	161
Long-term debt principal payments	(602)	0
Finance lease principal payments	(1,162)	(990)
Net cash provided by (used in) financing activities	14,064	(829)
Net decrease in cash, cash equivalents and restricted cash	(11,092)	(43,605)
Cash, cash equivalents and restricted cash, at beginning of period	86,202	100,668
Cash, cash equivalents and restricted cash, at end of period	75,110	57,063
Supplemental disclosures of cash flow information
Cash paid for interest	3,210	4,033
Cash paid for taxes	920	557
Stock consideration paid pursuant to exercise of Perceptive warrant	0	12,586
Purchases of property and equipment in accounts payable and accrued expenses	5,752	501
Assets acquired under capital lease obligations	$ 0	$ 689

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	28,708,058	28,016,545
Common stock, outstanding (in shares)	28,708,058	28,016,545

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Long-Term Debt - Connecticut Department of Economic and Community Development Funding Commitment (Details) - DECD Loan Agreement - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2017
Debt Instrument [Line Items]
Interest rate (as percent)			2.00%
Long-term debt principal payments	$ 0.3	$ 0.6
Outstanding loan balance	$ 5.2	$ 5.2

Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Prepaid expenses	$ 8,377	$ 7,425
Other current assets	1,942	1,079
Total	$ 10,319	$ 8,504

Fair Value Measurements - Schedule of Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Financial Assets:
Total financial assets	$ 123,104	$ 114,576
Financial Liabilities:
Contingent consideration	4,289
Total financial liabilities	5,828	3,519
Money Market Funds
Financial Assets:
Cash, cash equivalents, fair value	62,976	57,907
US Treasury Securities
Financial Assets:
Cash, cash equivalents, fair value	31,984	30,990
Corporate and Municipal
Financial Assets:
Cash, cash equivalents, fair value	28,144	25,679
Level 1
Financial Assets:
Total financial assets	62,976	57,907
Financial Liabilities:
Contingent consideration	0
Total financial liabilities	1,056	2,415
Level 1 \| Money Market Funds
Financial Assets:
Cash, cash equivalents, fair value	62,976	57,907
Level 1 \| US Treasury Securities
Financial Assets:
Cash, cash equivalents, fair value	0	0
Level 1 \| Corporate and Municipal
Financial Assets:
Cash, cash equivalents, fair value	0	0
Level 2
Financial Assets:
Total financial assets	60,128	56,669
Financial Liabilities:
Contingent consideration	0
Total financial liabilities	483	1,104
Level 2 \| Money Market Funds
Financial Assets:
Cash, cash equivalents, fair value	0	0
Level 2 \| US Treasury Securities
Financial Assets:
Cash, cash equivalents, fair value	31,984	30,990
Level 2 \| Corporate and Municipal
Financial Assets:
Cash, cash equivalents, fair value	28,144	25,679
Level 3
Financial Assets:
Total financial assets	0	0
Financial Liabilities:
Contingent consideration	4,289
Total financial liabilities	4,289	0
Level 3 \| Money Market Funds
Financial Assets:
Cash, cash equivalents, fair value	0	0
Level 3 \| US Treasury Securities
Financial Assets:
Cash, cash equivalents, fair value	0	0
Level 3 \| Corporate and Municipal
Financial Assets:
Cash, cash equivalents, fair value	0	0
Public warrant liability
Financial Liabilities:
Warrant liabilities	1,056	2,415
Public warrant liability \| Level 1
Financial Liabilities:
Warrant liabilities	1,056	2,415
Public warrant liability \| Level 2
Financial Liabilities:
Warrant liabilities	0	0
Public warrant liability \| Level 3
Financial Liabilities:
Warrant liabilities	0	0
Private warrant liability
Financial Liabilities:
Warrant liabilities	483	1,104
Private warrant liability \| Level 1
Financial Liabilities:
Warrant liabilities	0	0
Private warrant liability \| Level 2
Financial Liabilities:
Warrant liabilities	483	1,104
Private warrant liability \| Level 3
Financial Liabilities:
Warrant liabilities	$ 0	$ 0

Business Combinations - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2025	May 05, 2025	Dec. 31, 2024
Intangible Asset, Acquired, Finite-Lived [Line Items]
Goodwill	$ 12,926		$ 0
Fabric Genomics
Intangible Asset, Acquired, Finite-Lived [Line Items]
Cash and cash equivalents		$ 272
Accounts receivable		510
Prepaid expenses and other current assets		334
Property and equipment, net		12
Other assets		59
Intangible assets, net		25,500
Operating lease right-of-use assets		854
Accounts payable and accrued expenses		(1,147)
Deferred revenue		(1,609)
Operating lease liability		(854)
Fair value of net assets acquired		23,931
Goodwill		12,926
Aggregate purchase price		$ 36,857
Business acquisition, goodwill, expected tax deductible amount	$ 0

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Pay vs Performance Disclosure
Net income (loss)	$ 10,809	$ (29,173)	$ 4,280	$ (49,412)

Fair Value Measurements - Narrative (Details) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended
	Apr. 15, 2025 USD ($) day $ / shares	Apr. 30, 2024 USD ($) shares	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) day $ / shares shares	Jun. 30, 2024 USD ($)	May 05, 2025 USD ($)	Dec. 31, 2024 USD ($) shares	Oct. 27, 2023 USD ($) shares	Sep. 04, 2021 $ / shares	Jul. 22, 2021 shares
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) \| shares			666,515		666,515						666,516
Expected term (in years)			5 years		5 years
Target share price of warrants or rights for redemption (in dollars per share) \| $ / shares			$ 594.00		$ 594.00
Redemption price per warrant (in dollars per share) \| $ / shares					$ 0.33
Number of days for written notice of redemption \| day					30
Minimum number of trading days \| day					30
Common stock, issued (in shares) \| shares			28,708,058		28,708,058			28,016,545
Outstanding loan balance			$ 55,150		$ 55,150
Other current liabilities			1,223		1,223
Fabric Genomics
Cash and Cash Equivalents [Line Items]
Change in fair value of warrants and contingent liabilities			(900)		(900)
Gross revenue			$ 4,300		$ 4,300		$ 3,400
Price per shares (in dollars per share) \| $ / shares	$ 93.0318
Number of trading days \| day	30
Class A Common Stock Equals or Exceeds, $18.00
Cash and Cash Equivalents [Line Items]
Minimum number of trading days \| day					20
Consecutive trading day threshold \| day					30
Public Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) \| shares			457,323		457,323						447,223
Private Placement Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) \| shares			209,192		209,192						219,293
Initial Warrant Shares
Cash and Cash Equivalents [Line Items]
Aggregate exercise price		$ 2,500
Common stock, issued (in shares) \| shares		645,414
Perceptive Warrant
Cash and Cash Equivalents [Line Items]
Change in fair value of warrants and contingent liabilities				$ (5,100)		$ (10,100)
Credit Agreement \| Perceptive Term Loan Facility
Cash and Cash Equivalents [Line Items]
Revolving credit facility									$ 75,000
Credit Agreement \| Perceptive Term Loan Facility \| Perceptive Warrant Liability
Cash and Cash Equivalents [Line Items]
Number of shares to purchase (in shares) \| shares									1,200,000
Credit Agreement \| Perceptive Term Loan Facility \| Initial Warrant Shares
Cash and Cash Equivalents [Line Items]
Number of shares to purchase (in shares) \| shares									800,000
Credit Agreement \| Perceptive Term Loan Facility \| Additional Warrant Shares
Cash and Cash Equivalents [Line Items]
Number of shares to purchase (in shares) \| shares									400,000
Private Placement Warrants \| GeneDx
Cash and Cash Equivalents [Line Items]
Change in fair value of warrants and contingent liabilities			$ 3,100	$ 700	$ 2,000	$ (400)
First Milestone Payment \| Fabric Genomics
Cash and Cash Equivalents [Line Items]
Cash payment	$ 10,500
Gross revenue	$ 6,000
Gross margin (as a percent)	69.00%
Amount obtained by multiplying milestone payment	$ 7,000
Amount obtained by dividing the quotient of milestone payment	8,000
Second Milestone Payment \| Fabric Genomics
Cash and Cash Equivalents [Line Items]
Cash payment	7,500
Gross revenue	$ 9,000
Gross margin (as a percent)	69.00%
Amount obtained by multiplying milestone payment	$ 5,000
Amount obtained by dividing the quotient of milestone payment	$ 12,000
Class A common stock
Cash and Cash Equivalents [Line Items]
Purchase of aggregate private placement warrants (shares) \| shares			1		1
Warrant exercise price (in dollars per share) \| $ / shares										$ 379.50
Target share price of warrants or rights for redemption (in dollars per share) \| $ / shares			$ 330.00		$ 330.00
Minimum number of trading days \| day					20
Consecutive trading day threshold \| day					30
Common stock threshold, number of trading days before notice of redemption \| day					3
Redemption on warrant holders (in dollars per share) \| $ / shares					$ 594.00
Class A common stock \| Class A Common Stock Equals or Exceeds, $18.00
Cash and Cash Equivalents [Line Items]
Minimum threshold price of common stock specified to send notice of redemption to the warrant holders (in dollars per share) \| $ / shares					594.00
Class A common stock \| Class A Common Stock Equals or Exceeds, $10.00
Cash and Cash Equivalents [Line Items]
Target share price of warrants or rights for redemption (in dollars per share) \| $ / shares			$ 330.00		330.00
Redemption price per warrant (in dollars per share) \| $ / shares					$ 3.30
Number of days for written notice of redemption \| day					30
Minimum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost			$ 21,800		$ 21,800
Maximum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost			37,500		37,500
Level 2 \| DECD Loan Agreement
Cash and Cash Equivalents [Line Items]
Outstanding loan balance			5,200		5,200			$ 5,800
Other current liabilities			1,200		1,200
Long-term debt, fair value			$ 4,500		$ 4,500

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (246)	$ (190)	$ 201	$ (272)
Effective tax rate	2.30%	0.60%	4.50%	0.50%

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax was a $0.2 million benefit and $0.2 million of expense for the three and six months ended June 30, 2025, respectively. Income tax was a benefit of $0.2 million and $0.3 million for the three and six months ended June 30, 2024, respectively. Income taxes for these periods are recorded at the Company’s estimated annual effective income tax rate, subject to adjustments for discrete events should they occur. The Company’s effective tax rate for the three and six months ended June 30, 2025 was (2.3%) and 4.5%, respectively. The Company’s effective tax rate for the three and six months ended June 30, 2024 was 0.6% and 0.5%, respectively. The difference between the Company’s effective tax rates in 2025 and 2024 compared to the U.S. statutory tax rate of 21% is primarily due to changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets. The Company currently has valuation allowances against a significant portion of its deferred tax assets primarily related to its net operating loss carryforwards and tax credit carryforwards. On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law. This legislation includes changes to U.S. federal tax law, which may be subject to further clarification and the issuance of interpretive guidance. The Company is assessing the legislation and its effect on its consolidated financial statements, which it expects to begin reflecting in the third fiscal quarter of 2025.

Segment Reporting - Narrative (Details)	6 Months Ended
Segment Reporting - Narrative (Details)	Jun. 30, 2025 segment
Segment Reporting [Abstract]
Number of reportable segments	1
Number of operating segments	1